Focus: Aptevo Therapeutics is a Seattle-based public biotech focused on oncology and hematology therapeutics, specializing in bispecific antibody platforms. The company is in early-stage development with no commercial products and minimal cash reserves.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Aptevo Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Aptevo Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Aptevo Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
+1 more
Aptevo Therapeutics (NASDAQ: APVO) outlines bispecific cancer pipeline and AML data - Stock Titan
Aptevo Therapeutics (NASDAQ: APVO) outlines bispecific cancer pipeline and AML data Stock Titan
[8-K] Aptevo Therapeutics Inc. Reports Material Event - Stock Titan
[8-K] Aptevo Therapeutics Inc. Reports Material Event Stock Titan
8-K Filing: Aptevo Therapeutics Inc. (APVO) (CIK 0001671584) — EX-99.1
EX-99.1
Aptevo Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Aptevo Therapeutics Inc. Auditor Raises 'Going Concern' Doubt marketscreener.com
Aptevo Therapeutics Inc expected to post a loss of $8.10 a share - Earnings Preview - TradingView
Aptevo Therapeutics Inc expected to post a loss of $8.10 a share - Earnings Preview TradingView
Aptevo (NASDAQ: APVO) elevates COO Jeff Lamothe to succeed CEO Marvin White - Stock Titan
Aptevo (NASDAQ: APVO) elevates COO Jeff Lamothe to succeed CEO Marvin White Stock Titan
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Constructing the cure: engineering the next wave of antibody and cellular immune therapies.
The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo